期刊
BIOMEDICINES
卷 9, 期 12, 页码 -出版社
MDPI
DOI: 10.3390/biomedicines9121809
关键词
glioblastoma multiforme; mTORC1; mTORC2; mTOR inhibitors; mTOR signaling
GBM, a deadly brain tumor, has limited treatment options and mTOR pathway plays a crucial role in its pathogenesis. Initial attempts with first-generation mTOR inhibitors lacked significant success in clinical trials, but the development of next-generation inhibitors offers new hope for the potential of mTOR inhibitors in GBM.
Glioblastoma multiforme (GBM), a grade IV astrocytoma, is a lethal brain tumor with a poor prognosis. Despite recent advances in the molecular biology of GBM, neuro-oncologists have very limited treatment options available to improve the survival of GBM patients. A prominent signaling pathway implicated in GBM pathogenesis is that of the mechanistic target of rapamycin (mTOR). Attempts to target the mTOR pathway with first-generation mTOR inhibitors appeared promising in the preclinical stage; however, results have been disappointing in clinical trials, owing to the heterogeneous nature of GBM, escape mechanisms against treatment, the blood-brain barrier, drug-related toxicities, and the imperfect design of clinical trials, among others. The development of next-generation mTOR inhibitors and their current evaluation in clinical trials have sparked new hope to realize the clinical potential of mTOR inhibitors in GBM. Meanwhile, studies are continuously furthering our understanding of mTOR signaling dysregulation, its downstream effects, and interplay with other signaling pathways in GBM tumors. Therefore, it remains to be seen whether targeting mTOR in GBM will eventually prove to be fruitful or futile.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据